Advertisement
YOU ARE HERE: LAT HomeCollections

O.C. BUSINESS PLUS | ORANGE COUNTY BRIEFLY

Treatment Using ICN Drug Gets EU Approval

March 29, 2001

Costa Mesa drug maker ICN Pharmaceuticals Inc. said Wednesday that the European Commission of the European Union has approved the marketing of a new combination treatment for the hepatitis C liver disease.

The company said in a press release that its partner in the treatment, Schering-Plough Corp., received authorization to sell its new interferon injection along with ICN's ribavirin capsules to treat adults who have had relapses or who have had no prior treatments.

Schering-Plough has been selling an earlier version of its interferon with the ICN product to treat hepatitis C in the 15-nation European Union. Schering has exclusive rights to market oral ribavirin for hepatitis C treatment in all major world markets through a licensing agreement with ICN.

Advertisement
Los Angeles Times Articles
|
|
|